NCT01319695

Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: National and Kapodistrian University of Athens · Academic / Other
• Sex: Female
• Age: 18 Years – 36 Years
• Healthy volunteers: Accepted

Summary

The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation protocols in women undergoing in vitro fertilisation.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	corifollitropin alfa	100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg
DRUG	recombinant follicle stimulating hormone (FSH)	150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm

Timeline

• Start date: 2011-01-01
• Primary completion: 2016-07-01
• Completion: 2017-08-01
• First posted: 2011-03-22
• Last updated: 2021-03-17

Locations

2 sites across 1 country: Greece